HAIFA, Israel, April 24, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the European Investment Bank (EIB) has approved a 50 million non-dilutive financing for the Company (the Approved Financing). This Approved Financing, once received, will support Pluristems research and development in the EU to further advance its regenerative cell therapy platform, and to assist moving the products in its pipeline to market, with a special focus on clinical development of PLX cells as a treatment for complications associated with COVID-19. The Approved Financing will be deployed in three tranches, subject to the achievement of certain clinical, regulatory and scaling up milestones, with the first tranche consisting of 20 million. The expected signing date of the financing agreement relating to the Approved Financing is April 30, 2020.
Pluristem recently formed a wholly-owned subsidiary in Berlin, Germany, underscoring the Companys commitment to having a physical presence in Europe to advance research and development, and to prepare for commercialization, for its product candidates.
The Approved Financing is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the financial pillar of the Investment Plan for Europe, under which the EIB and the European Commission are working together as strategic partners to boost Europes economic competitiveness. The transaction has been initiated by kENUP Foundation, a global partnership in innovation, promoting research-based innovation for Europe with public and societal benefit.
The Approved Financing, once granted, will not be secured and will be payable to the EIB in a single payment following five years from the disbursement of the first and second tranches and in two annual payments starting on the fourth year from disbursement of the third tranche, with each tranche having an interest rate of between 3% to 4%. The Approved Financing will support up to 50% of Pluristems R&D project cost. In addition, the EIB would be entitled to receive royalties from future revenues for a period of seven years starting 2024, at a rate of 0.2% to 2.3%, pro-rated to the amounts that the Company received from the Approved Financing.
We are extremely honored to have been selected by the EIB for this prestigious financing. We believe that this financing will allow us to significantly advance the clinical development of our lead product candidates, which if successful we expect will improve the quality of life for millions of patients around the world. Having established research partnerships with leading European institutions such as Charit University of Medicine Berlin, BIH Center for Regenerative Therapy (BCRT) and the Berlin Center for Advanced Therapies (BeCAT), as well as formed a subsidiary in Berlin, we understand the importance of having a physical presence in key markets, stated Pluristem CEO and President, Yaky Yanay. As we move forward into a multinational clinical trial for PLX cells to treat patients suffering from complications associated with COVID-19, we expect this EIB financing will accelerate our path to approval and to making a potentially effective COVID-19 treatment available worldwide.
About the European Investment Bank The European Investment Bank (EIB) is the long-term lending institution of the European Union, owned by its Member States. It makes long-term finance available for sound investment in order to contribute towards EU policy goals.
Investment Plan for Europe The Investment Plan for Europe (the Juncker Plan) is one of the EU's key actions to boost investment in Europe, thereby creating jobs and fostering growth. To this end, smarter use will be made of new and existing financial resources. The EIB Group, consisting of the European Investment Bank and the European Investment Fund, is playing a vital role in this investment plan. With guarantees from the European Fund for Strategic Investments (EFSI), the EIB and EIF are able to take on a higher share of project risk, encouraging private investors to participate in the projects. In addition to EFSI, the new European Investment Advisory Hub (EIAH) helps public and private sector project promoters to structure investment projects more professionally. The projects and agreements approved under EFSI (European Fund for Strategic Investments) so far are expected to mobilise almost 466 billion of investments and will benefit over 1 million start-ups and SMEs (Small Medium Enterprises) in the 27 Member States.
About Pluristem TherapeuticsPluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a Company-owned and operated GMP-certified manufacturing and research facility; strategic relationships with major research institutions; and a seasoned management team.
Safe Harbor Statement This press release contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluristem is using forward-looking statements when it discusses its expectation that it will execute a definitive agreement for the Approved Financing and the proposed terms of such Approved Financing, the belief that the Approved Financing will support its research and development in the EU to further advance its regenerative cell therapy platform, to assist moving the products in its pipeline to market, with a special focus on clinical development of PLX cells as a treatment for complications associated with COVID-19, that such Approved Financing will allow it to significantly advance its clinical development of its lead product candidates which it expects will improve the quality of life for millions of patients around the world and the expectation that the Approved Financing will accelerate its path to approval of its COVID-19 multinational clinical trial and to making a potentially effective COVID-19 treatment available worldwide. While the EIB has announced the approval of the Approved Financing, there is no guarantee that the Company and the EIB will execute the definitive agreement on April 30, 2020, if at all, or that it will achieve the milestones necessary to receive any or all of the three tranches. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; Pluristem may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Pluristems products may not be approved by regulatory agencies, Pluristems technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Pluristem may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Pluristems process; Pluristems products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Pluristems patents may not be sufficient; Pluristems products may harm recipients; changes in legislation may adversely impact Pluristem; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
Contact:Dana RubinDirector of Investor Relations+972-74-7107194danar@pluristem.com
See the original post:
Pluristem Secures 50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III StudiesEXPECTED...
- Molecular discovery has potential to solve the billion-dollar global cost of poorly managed wound healing - Medical Xpress - March 29th, 2024
- Science Saturday: A year of new directions and advancements for ... - March 29th, 2024
- Diverse ways regenerative medicine is advancing health care - March 29th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 29th, 2024
- Global Organoids and Spheroids Market Set for Remarkable Growth, Reaching USD 7.70 Billion by 2034 with a CAGR ... - GlobeNewswire - March 29th, 2024
- Growth Projections for the Regenerative Medicine Market - BioProcess Insider - March 10th, 2024
- Regenerative Medicine - Cell Therapies - BioProcess Insider - March 10th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 10th, 2024
- Stem cell-based regenerative medicine - PMC - National Center for ... - February 27th, 2024
- Unlocking the Mysteries of the Hippo Pathway: A Leap Towards Conquering Cancer and Regenerating Tissues - Medriva - February 27th, 2024
- PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market - Yahoo Finance - February 27th, 2024
- Therapeutic Solutions International Files Patent on "Facilitating Effects" of JadiCells on Gene Therapy Mediated Cell ... - Yahoo Finance - February 27th, 2024
- RION Expands Manufacturing Operations with Cutting-Edge Facility in Rochester, Minnesota - Yahoo Finance - February 27th, 2024
- Hands-On Solutions: Applying Prosthetic Sensory Technology In Rehabilitation - Forbes - February 27th, 2024
- UC Irvine Embarks on a Transformative Journey in Stem Cell Research with a $4 Million Boost - BNN Breaking - February 27th, 2024
- Less Surgery, More Recovery: Here is How Regenerative Medicine is Shaping the Future for Neurosurgeons - News Channel Nebraska - February 27th, 2024
- SPONSORED: Regen Rx Offers Both Non-Invasive Regenerative Medicine Procedures and Ultrasound-Guided ... - exploreClarion.com - February 27th, 2024
- ROSM Celebrates 10 Years of Advancing Patient Care Through Regenerative Medicine - goskagit.com - February 27th, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 27th, 2024
- Regenerative medicine | NIST - February 10th, 2024
- Home - Kansas Regenerative Medicine - February 10th, 2024
- Translational Regenerative Medicine market is estimated to grow at a CAGR of 24.3% by 2034: Visiongain - Yahoo Finance - February 10th, 2024
- Cellular senescence is associated with osteonecrosis of the femoral head while mesenchymal stem cell conditioned ... - Nature.com - February 10th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 10th, 2024
- Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024 - Yahoo Finance - February 10th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 10th, 2024
- Innovative stem cell therapy could be "game changer" in epilepsy - The Pharma Letter - February 10th, 2024
- Neurona lands $120m to advance regenerative cell therapy pipeline - Longevity.Technology - February 10th, 2024
- Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates ... - GlobeNewswire - February 10th, 2024
- Treating Joint Problems in the Modern Age: How Regenerative Medicine Paves the Way - Health shots - February 10th, 2024
- Cancer-related mutations appear in stem cell derivatives used in regenerative medicine, shows study - Phys.org - January 17th, 2024
- Researchers genetically modify stem cells to evade immunological rejection - University of Arizona - January 17th, 2024
- The Impact and Implications of Regenerative Medicine in Urology - Cureus - January 17th, 2024
- LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley - The Morning Call - January 17th, 2024
- Clinical applications of stem cell-derived exosomes | Signal Transduction and Targeted Therapy - Nature.com - January 17th, 2024
- Therapeutic Solutions International Launches Adult Stem Cell Therapy Company Focused on Curing Epilepsy - Business Wire - January 17th, 2024
- Cell Therapy Technologies Market Projected to Reach Valuation of USD 47.3 Billion at 24.7% CAGR from 2024-2033 ... - GlobeNewswire - January 17th, 2024
- Cancer Mutations in 22% of Stem Cells: Concern for Regenerative Medicine - BNN Breaking - January 17th, 2024
- San Jose blood stem cell donor meets 15-year-old whose life he saved in Los Angeles - The Mercury News - May 17th, 2023
- Regenerative medicine: Current therapies and future directions - April 23rd, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - April 23rd, 2023
- Important Patient and Consumer Information About Regenerative Medicine ... - April 23rd, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 23rd, 2023
- About Regenerative Medicine - Center for Regenerative ... - Mayo Clinic - April 7th, 2023
- Regenerative Medicine | National Institutes of Health (NIH) - April 7th, 2023
- Porcine Vaccine Market is estimated to be US$ 4.41 billion by 2030 with a CAGR of 7.50%during the forecast - EIN News - April 7th, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 21st, 2023
- Active Wound Care Market Rising demand for Skin Substitutes to boost the industry (2023-2033) | CAGR of 5.5% - EIN News - March 21st, 2023
- Veterinary Orthopedic Implants Market is estimated to be 421.3 Million by 2029 with a CAGR of 5.3% - By PMI - EIN News - March 21st, 2023
- ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical VHH to address an unmet medical... - February 8th, 2023
- A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field - Yahoo Finance - October 15th, 2022
- The Switch to Regenerative Medicine - Dermatology Times - October 15th, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 15th, 2022
- Mathematical model could bring us closer to effective stem cell therapies - Michigan Medicine - October 15th, 2022
- 'We have to find a way': FDA seeks solutions to aid bespoke gene therapy - BioPharma Dive - October 15th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - GlobeNewswire - October 15th, 2022
- Discover Medical Advances in Cellular Therapy Research Using Cord Blood for Cancer, HIV, Cerebral Palsy and Autism During World Cord Blood Day 2022 -... - October 15th, 2022
- The Risk-Reward Proposition for CGT Clinical Trials - Applied Clinical Trials Online - October 15th, 2022
- Cell therapy weekly: Ray Therapeutics and Forge Biologics expand partnership - RegMedNet - October 15th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 15th, 2022
- Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Business Wire - October 15th, 2022
- The Health Benefits Of Sea Moss, According To Experts - Forbes - October 15th, 2022
- ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of ... - The Bakersfield Californian - October 15th, 2022
- Pain Management & Regenerative Medicine Specialists DFW - September 4th, 2022
- Tissue Engineering and Regenerative Medicine - National Institute of ... - September 4th, 2022
- First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov) - September 4th, 2022
- International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review - September 4th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - September 4th, 2022
- Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace - September 4th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 4th, 2022
- TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all... - September 4th, 2022
- Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire - September 4th, 2022
- Can the immortal jellyfish teach us how to reverse aging? - Earth.com - September 4th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - September 4th, 2022
- Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors - PR Newswire - September 4th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 4th, 2022
- Regenerative Medicine Partnering 2015 to 2022: Terms and Agreements Entered Into by the Leading Companies Worldwide - ResearchAndMarkets.com -... - August 19th, 2022
- Pain Relief Treatments: The Benefits of Regenerative Medicine From Head to Toe - 30Seconds.com - August 19th, 2022
- FDA Issues Draft Guidance to Facilitate Development of Human Gene Therapy, CAR T Cell, and Regenerative Medicine Products - Wilson Sonsini Goodrich... - August 19th, 2022
- Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert - August 19th, 2022